Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy

SIMPLE SUMMARY: Despite recent advances in the treatment of other breast cancer subtypes, inflammatory breast cancer (IBC) remains a significant clinical challenge, with an overall 5-year survival rate of 39%. Though immunotherapy has shown remarkable efficacy in other difficult-to-treat cancers, su...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch, Regina M., Principe, Daniel R., Cataneo, Jose L., Rana, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196819/
https://www.ncbi.nlm.nih.gov/pubmed/34067257
http://dx.doi.org/10.3390/cancers13112543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8196819/
https://www.ncbi.nlm.nih.gov/pubmed/34067257
http://dx.doi.org/10.3390/cancers13112543

Ejemplares similares